

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

VOLUNTARY ANNOUNCEMENT BY CLEAR LEAD VENTURES LIMITED DISPOSAL OF SHARES BY A SUBSTANTIAL SHAREHOLDER

This announcement is made by Clear Lead Ventures Limited (the “**Seller**”), a substantial shareholder (as defined under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”)) of Clarity Medical Group Holding Limited (the “**Company**”), on a voluntary basis.

Reference is made to the voluntary announcement of the Seller dated 14 January 2025 (the “**Announcement**”) in relation to its disposal of certain shares in the Company to Innovative Vision Inc (the “**Buyer**”). Unless otherwise defined, capitalised terms used herein shall have the same meanings as defined in the Announcement.

UPDATE ON THE NEW OFFER

In connection with the offer extended from the Buyer to the Seller on 13 January 2025 with respect to the sale of 46,015,790 Shares, on 14 February 2025, the Seller and the Buyer have conditionally agreed to the sale of 46,015,790 Shares (the “**Sale Shares**”), representing approximately 8.7% of the total issued share capital of the Company as of the date hereof, by the Seller to the Buyer (the “**Sale Transaction**”).

On 31 March 2025, the Buyer and the Seller entered into a sale and purchase agreement (the “**8.7% SPA**”) in connection with the Sale Transaction. On the date of execution of the 8.7% SPA and as of the date hereof, the Seller is a substantial shareholder (as defined under the Listing Rules) of the Company, holding 58,404,950 Shares, representing approximately 11.04% of the total issued share capital of the Company. Upon consummation of the closing of the Sale Transaction, the Seller will hold 12,389,160 Shares (the “**Residue Shares**”), representing approximately 2.34% of the total issued share capital of the Company as of the date hereof.

The key terms of the 8.7% SPA are set forth below:

- | | |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| The Sale Transaction: | The Seller has conditionally agreed to sell and the Buyer has conditionally agreed to purchase the Sale Shares |
| Consideration: | HK\$25,000,000, which is equivalent to approximately HK\$0.5433 per Sale Share |
| Representations and Covenants: | (1) The Seller and the Buyer are independent from and are not connected with each other; and they do not act in concert (as defined under the Hong Kong Codes on Takeovers and Mergers); |

- (2) the Seller must, after the date of closing of the Sale Transaction, sell the Residue Shares in the open market;
- (3) The Buyer does not exercise any control, assert any influence and hold any option on the Residue Shares.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the board of
CLEAR LEAD VENTURES LIMITED
CHAN Hoi Hin William
Director

Hong Kong, 31 March 2025

As at the date of this announcement, the board of Clear Lead Ventures Limited comprises Mr. CHAN Hoi Hin William and Mr. GOH Lu Hong as the directors.